8 Mesothelioma Diagnostic Biomarkers Advancing Early Detection in 2026

Q: Is there an FDA-approved blood test for mesothelioma?

Yes, but only one. The MESOMARK assay, cleared by the FDA in January 2007, measures soluble mesothelin-related peptides (SMRP) in blood serum. It is approved for monitoring disease progression in patients already diagnosed with epithelioid or biphasic mesothelioma — not for initial screening or diagnosis. MESOMARK has a pooled sensitivity of 61% and specificity of 87%, meaning it misses roughly 4 in 10 cases. No new blood-based biomarker has received FDA approval since 2007.

Q: What is the most accurate mesothelioma biomarker available today?

No single biomarker is accurate enough to diagnose mesothelioma alone. The highest published accuracy comes from multi-marker panels: the SOMAmer 13-protein classifier achieved 92% overall accuracy and detected 88% of early-stage disease, while a three-protein combination of mesothelin, fibulin-3, and HMGB1 reached 96% sensitivity and 93% specificity. BAP1 immunohistochemistry on tissue samples offers near-complete specificity for distinguishing benign from malignant mesothelial disease.

Q: Can a liquid biopsy detect mesothelioma?

Not yet in routine clinical practice, but research is advancing. A 2025 study presented at ASCO demonstrated that cfMeDIP-seq — a methylation-based liquid biopsy — achieved 91% accuracy in distinguishing pleural mesothelioma from non-cancer controls using a blood draw. A separate 2025 trial published in Nature Medicine showed that ctDNA monitoring detected disease progression before imaging in resectable mesothelioma patients. Neither approach has received FDA approval, but both represent significant progress toward a blood-based diagnostic.

Q: What is BAP1 testing and why does it matter for mesothelioma diagnosis?

BAP1 (BRCA1-associated protein-1) immunohistochemistry is a tissue-based test that detects loss of the BAP1 tumor suppressor protein. Loss of BAP1 staining in mesothelial cells has near-complete specificity for malignancy, making it the single most important tool pathologists use to distinguish benign mesothelial proliferations from mesothelioma. Approximately 60% of mesothelioma tumors show somatic BAP1 loss. Patients with germline BAP1 mutations have a dramatically different prognosis, with 5-year survival rates of 47% compared to 6.7% in the general mesothelioma population.

Q: How is AI being used in mesothelioma diagnosis?

AI-assisted pathology tools are being developed to improve diagnostic accuracy and speed, though none have received FDA approval specifically for mesothelioma. A landmark 2025 study published in Nature used deep learning to analyze 3,446 whole-slide images and identified 47 recurring tissue patterns linked to survival outcomes, outperforming human grading for epithelioid cases. SpindleMesoNET, a convolutional neural network, distinguished sarcomatoid mesothelioma from benign conditions with 92.5% accuracy. Paige PanCancer Detect received FDA Breakthrough Device designation in April 2025 for multi-tissue cancer detection.

Q: Why is mesothelioma so hard to detect early?

Mesothelioma is difficult to detect early because symptoms like shortness of breath and chest pain mimic common conditions, the disease has a 20-to-50-year latency period after asbestos exposure, and fewer than 5% of patients are diagnosed at stage I. The cancer's rarity — approximately 3,000 new U.S. cases per year — also limits the size of clinical studies needed to validate new diagnostic tools. Additionally, mesothelioma lacks recurrent driver mutations, making standard genetic screening approaches less effective.

Q: Should asbestos-exposed workers get regular biomarker screening?

No blood-based biomarker test is currently recommended for routine screening of asbestos-exposed individuals. Prospective studies have not demonstrated that SMRP screening improves outcomes in high-risk populations. However, asbestos-exposed workers should discuss their exposure history with their physician and undergo regular medical monitoring, including imaging when symptoms develop. Multi-marker panels and liquid biopsies in clinical trials represent the most promising path toward validated screening for high-risk groups.

Executive Summary

Only one FDA-approved blood test for mesothelioma exists — the MESOMARK assay, cleared in 2007 — and it detects just 61% of cases. But 8 diagnostic biomarkers and detection tools are advancing rapidly toward clinical use. Multi-marker blood panels now achieve over 90% accuracy. Methylation-based liquid biopsies reached 91% accuracy in a 2025 proof-of-concept study. AI-assisted pathology outperformed expert pathologists in subtype classification. And BAP1 immunohistochemistry has become the definitive tissue test for distinguishing benign from malignant mesothelial disease. Fewer than 5% of patients are currently diagnosed at stage I, when treatment is most effective — making each of these advances critical for the roughly 3,000 Americans diagnosed annually. [1][2]

FDA-approved mesothelioma blood test (MESOMARK, since 2007)

61%

Sensitivity of the MESOMARK assay — misses nearly 4 in 10 cases

92%

Accuracy of the SOMAmer 13-protein panel in clinical studies

<5%

Mesothelioma patients diagnosed at stage I, when prognosis is best

Key Facts About Mesothelioma Diagnostic Biomarkers

1 FDA-approved blood biomarker — MESOMARK (SMRP) was cleared in January 2007 for monitoring, not diagnosis [13]
61% sensitivity, 87% specificity — pooled MESOMARK performance from a meta-analysis of 28 studies [13]
92% overall accuracy — achieved by the SOMAmer 13-protein classifier, detecting 88% of stage I and II disease [14]
96% sensitivity, 93% specificity — reached by a three-protein panel combining mesothelin, fibulin-3, and HMGB1 [9]
91% accuracy — cfMeDIP-seq methylation liquid biopsy in a 2025 ASCO proof-of-concept study [7]
89.2% sensitivity, 93.5% specificity — IMPRESS tissue methylation assay distinguishing tumor from normal pleura [5]
60% of mesothelioma tumors — show somatic BAP1 loss, making BAP1 IHC the top tissue-based diagnostic marker [16]
47% five-year survival — for patients with germline BAP1 mutations, compared to 6.7% in the general population [12]
88% AUC for subtype classification — achieved by AI deep learning on 3,446 whole-slide histology images [4]
20-50 year latency period — between asbestos exposure and mesothelioma diagnosis, complicating early screening [11]

Why Is Early Detection of Pleural Mesothelioma So Difficult?

Pleural mesothelioma is diagnosed at an advanced stage in the vast majority of cases. Fewer than 5% of patients receive a stage I diagnosis, when surgical intervention and multimodal treatment offer the strongest outcomes. [1][2] The disease's 20-to-50-year latency period between asbestos exposure and symptom onset means that by the time patients develop persistent chest pain, shortness of breath, or unexplained pleural effusions, the cancer has typically spread beyond the pleural lining. [11]

Mesothelioma's biology compounds the problem. The cancer is driven primarily by loss of tumor suppressor genes — BAP1, NF2, and CDKN2A — rather than by gain-of-function mutations that standard genetic tests can flag. [12] With approximately 3,000 new U.S. cases per year, the disease is rare enough that validating new diagnostic tools requires multicenter international collaboration. [1]

The current diagnostic pathway typically begins with imaging, followed by thoracentesis or tissue biopsy for histological confirmation — an invasive process that delays treatment. Blood-based biomarkers, liquid biopsies, and AI-assisted pathology represent the three frontiers working to close that gap.

"When I explain to families that only one blood test is FDA-approved for mesothelioma — and it's for monitoring, not even initial diagnosis — the reaction is always disbelief. The research pipeline is moving faster than most people realize, and that gives us genuine reasons to push for earlier screening in high-risk populations."

— David Foster, Executive Director of Client Services, Danziger & De Llano

What Is the Only FDA-Approved Mesothelioma Blood Test?

The MESOMARK assay remains the sole FDA-approved serum biomarker for mesothelioma, nearly two decades after its clearance in January 2007. Developed by Fujirebio Diagnostics, MESOMARK measures soluble mesothelin-related peptides (SMRP) in blood serum. [13] SMRP levels correlate with tumor volume, making the test useful for tracking disease progression and treatment response in patients already diagnosed with epithelioid or biphasic mesothelioma.

MESOMARK was not approved for primary diagnosis or screening. A meta-analysis of 28 studies found pooled sensitivity of 61% and specificity of 87%. [13] At the high-specificity thresholds needed for population screening (99% specificity), sensitivity drops to just 23% — meaning the test would miss more than 3 out of 4 cases in an asbestos-exposed population. The test performs worst for sarcomatoid mesothelioma, where mesothelin expression is often low or absent.

In clinical practice, MESOMARK is available through reference laboratories including ARUP Laboratories. A 25% change in serum mesothelin from baseline is considered the optimal threshold for detecting disease progression, though sensitivity for progression detection is modest at 48.7%.

Which Emerging Blood Biomarkers Show the Most Promise for Mesothelioma?

Three blood-based biomarkers are generating significant research interest, though none have received FDA approval.

Fibulin-3

Fibulin-3 made headlines in 2012 when a landmark study in the New England Journal of Medicine reported 96.7% sensitivity and 95.5% specificity for distinguishing mesothelioma from asbestos-exposed controls. [8] Subsequent validation produced mixed results. A 2025 prospective study of 90 patients found 100% specificity but only 39.39% sensitivity at a plasma cutoff of 12.31 ng/mL, confirming that fibulin-3 is highly specific but inconsistently sensitive as a standalone test. Its primary value lies in multi-marker panels.

HMGB1 (High Mobility Group Box 1)

HMGB1, specifically its hyperacetylated isoform, plays a direct role in asbestos carcinogenesis. When asbestos fibers damage mesothelial cells, they release HMGB1, triggering chronic inflammation. A 2016 study in Clinical Cancer Research reported that hyperacetylated HMGB1 distinguished mesothelioma patients from asbestos-exposed controls with 100% sensitivity and 100% specificity at a cutoff of 2.00 ng/mL. [9] These results require independent large-scale validation — an expression of concern was published regarding aspects of the original data — but the mechanistic link between HMGB1 and asbestos exposure makes it a biologically compelling candidate.

The SOMAmer 13-Protein Panel

The most promising multi-marker approach is the SOMAmer 13-protein classifier developed by SomaLogic. Using simultaneous measurement of 13 proteins in blood serum, the panel achieved 92% overall accuracy with detection of 88% of stage I and stage II disease in blinded validation — substantially outperforming single-marker mesothelin testing (66% sensitivity, 88% specificity) in the same patient populations. [14] The DIAPHRAGM prospective multicenter study was designed to validate these results in clinical settings.

The strongest published combination to date: a three-protein panel of mesothelin, fibulin-3, and HMGB1 achieved 96% sensitivity and 93% specificity — far exceeding any individual biomarker. [9]

"No single blood test can reliably detect mesothelioma on its own. The science is converging on panels — combinations of 3 to 13 proteins that together catch what any single marker would miss. For patients with occupational asbestos exposure, these multi-marker panels represent the most realistic path to routine screening."

— David Foster, Executive Director of Client Services, Danziger & De Llano

How Are Liquid Biopsies and DNA Methylation Changing Mesothelioma Detection?

Liquid biopsy — detecting cancer signals from a standard blood draw — faces a unique challenge in mesothelioma. Unlike cancers with recurrent oncogene mutations, mesothelioma is driven by loss-of-function changes in tumor suppressor genes (BAP1, NF2, CDKN2A). Conventional mutation-based circulating tumor DNA (ctDNA) assays have poor sensitivity because there are few consistent mutation targets to track. [3]

The breakthrough is epigenetic: instead of searching for mutations, researchers are analyzing methylation patterns in cell-free DNA — a signal that is abundant and distinct in mesothelioma even with a low mutational burden.

cfMeDIP-seq: 91% accuracy from a blood draw

The most promising liquid biopsy result for mesothelioma was presented at the 2025 ASCO Annual Meeting. Cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) analyzed plasma from 55 pleural mesothelioma patients and 24 asbestos-exposed controls. A random forest classifier achieved 91% accuracy, 88% precision, and 90% recall for distinguishing mesothelioma from non-cancer controls. [7] The classifier also distinguished histological subtypes — epithelioid, biphasic, and sarcomatoid — potentially enabling non-invasive subtype identification before biopsy.

ctDNA for treatment monitoring

A pivotal 2025 trial published in Nature Medicine demonstrated that tumor-informed ctDNA monitoring detected disease progression in resectable pleural mesothelioma patients before conventional imaging could. [3] Patients with undetectable ctDNA after neoadjuvant immunotherapy had significantly longer event-free survival, while persistent ctDNA correlated with early relapse. The study used whole-genome sequencing coupled with machine learning to overcome mesothelioma's low mutation burden. [15]

IMPRESS tissue methylation assay

The IMPRESS assay, published in Molecular Oncology in 2025, uses a bisulfite-free technique analyzing 744 hypermethylated CpG sites. The two-step classifier achieved 89.2% sensitivity and 93.5% specificity for distinguishing tumor from normal pleura, and 85.2% sensitivity with 100% specificity for separating primary mesothelioma from pleural metastases. [5] This second distinction is particularly valuable — differentiating primary mesothelioma from metastatic disease in the pleura is one of the most challenging problems in thoracic pathology.

What Role Does AI Play in Mesothelioma Pathology?

No AI-assisted pathology tool has received FDA approval specifically for mesothelioma diagnosis. However, research-stage models are producing results that match or exceed expert pathologists in specific tasks. [4]

The 2025 Nature histomorphological atlas

The most significant AI advance in mesothelioma pathology was a landmark study published in Nature Communications in 2025. Researchers applied unsupervised deep learning to 3,446 whole-slide images from resected mesothelioma specimens, identifying 47 recurring histomorphological phenotype clusters (HPCs) linked to tumor biology and outcomes. [4] The model achieved 88% AUC for subtype classification and outperformed human grading in survival prediction for epithelioid cases. It was validated across three independent cohorts without retraining.

SpindleMesoNET

This convolutional neural network distinguishes sarcomatoid mesothelioma from benign spindle cell mesothelial proliferations with an AUC of 0.989 and accuracy of 92.5% — higher than the average 91.7% accuracy of three experienced pathologists in the same study.

Paige PanCancer Detect

In April 2025, Paige received FDA Breakthrough Device designation for PanCancer Detect, an AI application that identifies cancer across multiple tissue types and organ sites. [10] While not mesothelioma-specific, this multi-site detection capability could flag mesothelioma specimens in clinical pathology workflows. Paige has regulatory precedent: its Paige Prostate was the first FDA-authorized AI tool in histopathology.

How Does BAP1 Testing Distinguish Benign From Malignant Disease?

BAP1 (BRCA1-associated protein-1) immunohistochemistry has become the most clinically impactful diagnostic advance in mesothelioma pathology to reach routine practice. Loss of nuclear BAP1 staining in mesothelial cells has near-complete specificity for malignancy — making it the definitive tissue-based test for distinguishing benign mesothelial proliferations from mesothelioma. [16]

Approximately 60% of mesothelioma tumors show somatic BAP1 loss by next-generation sequencing, while an estimated 1% of sporadic cases carry germline BAP1 mutations. About 20% of all mesothelioma cases involve some form of genetic predisposition. [16][12]

The clinical significance of germline BAP1 mutations is profound. Patients with BAP1 tumor predisposition syndrome develop mesothelioma at a median age of 54-56 years (compared to 72 in sporadic cases), have nearly equal gender distribution (versus the 5:1 male predominance in asbestos-related disease), and present with almost exclusively epithelioid histology. Most strikingly, 5-year survival reaches 47% in germline BAP1 carriers — a seven-fold improvement over the 6.7% observed in the general SEER population. [12]

"BAP1 testing has fundamentally changed how pathologists evaluate suspicious pleural tissue. When a biopsy shows loss of BAP1 staining, the probability of malignancy is near-certain. For families with a history of mesothelioma — especially those diagnosed younger than expected — germline BAP1 testing can identify relatives at elevated risk and guide proactive screening."

— David Foster, Executive Director of Client Services, Danziger & De Llano

What Does the Future of Mesothelioma Early Detection Look Like?

The overriding theme of 2025-2026 mesothelioma diagnostics is convergence. Single-biomarker strategies are giving way to multi-modal approaches that combine blood proteins, epigenetic signals, tissue markers, and computational pathology. The highest-performing approaches all involve marker combinations:

Blood protein panels: Mesothelin + fibulin-3 + HMGB1 (96% sensitivity, 93% specificity) [9]
Tissue methylation: SHOX2 + PTGER4 + CYFRA21-1 (91.3% sensitivity, 97.6% specificity) [6]
Liquid biopsy: cfMeDIP-seq methylation profiling (91% accuracy) [7]
AI histopathology: Whole-slide image analysis with 47 phenotype clusters (88% AUC for subtype classification) [4]

The primary bottleneck is validation. Mesothelioma's rarity — 3,000 U.S. cases annually — means that the proof-of-concept studies powering these results involve dozens to hundreds of patients, not thousands. Multicenter international consortia and data-sharing agreements are essential to generate the registration-quality evidence needed for FDA approval.

For patients and families dealing with an asbestos exposure history, the practical message is clear: the science of mesothelioma detection is advancing on multiple fronts simultaneously. Patients diagnosed today should ask their oncology team about available biomarker monitoring (MESOMARK for disease tracking, BAP1 testing for tissue specimens) and inquire about clinical trials testing next-generation diagnostics. Families with a strong history of mesothelioma or related cancers should discuss germline BAP1 testing with a genetic counselor.

Understanding your legal rights is equally important. If you or a family member has been diagnosed with mesothelioma, asbestos trust funds hold over $30 billion for victims. Danziger & De Llano specializes exclusively in mesothelioma litigation and can help you pursue every available compensation source — including asbestos exposure claims and trust fund filings — while you focus on treatment. Take our free case assessment or call (855) 699-5441 to speak with our team.

Frequently Asked Questions

Is there an FDA-approved blood test for mesothelioma?

Yes, but only one. The MESOMARK assay, cleared by the FDA in January 2007, measures soluble mesothelin-related peptides (SMRP) in blood serum. It is approved for monitoring disease progression in patients already diagnosed with epithelioid or biphasic mesothelioma — not for initial screening or diagnosis. MESOMARK has a pooled sensitivity of 61% and specificity of 87%, meaning it misses roughly 4 in 10 cases. No new blood-based biomarker has received FDA approval since 2007. [13]

What is the most accurate mesothelioma biomarker available today?

No single biomarker is accurate enough to diagnose mesothelioma alone. The highest published accuracy comes from multi-marker panels: the SOMAmer 13-protein classifier achieved 92% overall accuracy and detected 88% of early-stage disease, while a three-protein combination of mesothelin, fibulin-3, and HMGB1 reached 96% sensitivity and 93% specificity. [14][9] BAP1 immunohistochemistry on tissue samples offers near-complete specificity for distinguishing benign from malignant mesothelial disease. [16]

Can a liquid biopsy detect mesothelioma?

Not yet in routine clinical practice, but research is advancing. A 2025 study presented at ASCO demonstrated that cfMeDIP-seq — a methylation-based liquid biopsy — achieved 91% accuracy in distinguishing pleural mesothelioma from non-cancer controls using a blood draw. [7] A separate 2025 trial published in Nature Medicine showed that ctDNA monitoring detected disease progression before imaging in resectable mesothelioma patients. [3] Neither approach has received FDA approval.

What is BAP1 testing and why does it matter for mesothelioma diagnosis?

BAP1 (BRCA1-associated protein-1) immunohistochemistry is a tissue-based test that detects loss of the BAP1 tumor suppressor protein. Loss of BAP1 staining in mesothelial cells has near-complete specificity for malignancy, making it the single most important tool pathologists use to distinguish benign mesothelial proliferations from mesothelioma. [16] Approximately 60% of mesothelioma tumors show somatic BAP1 loss. [16] Patients with germline BAP1 mutations have 5-year survival rates of 47% compared to 6.7% in the general mesothelioma population. [12]

How is AI being used in mesothelioma diagnosis?

AI-assisted pathology tools are in development, though none have FDA approval specifically for mesothelioma. A landmark 2025 study in Nature Communications used deep learning to analyze 3,446 whole-slide images and identified 47 recurring tissue patterns linked to survival outcomes, outperforming human grading for epithelioid cases. [4] SpindleMesoNET achieved 92.5% accuracy distinguishing sarcomatoid mesothelioma from benign conditions. Paige PanCancer Detect received FDA Breakthrough Device designation in April 2025 for multi-tissue cancer detection. [10]

Why is mesothelioma so hard to detect early?

Mesothelioma is difficult to detect early because symptoms like shortness of breath and chest pain mimic common conditions, the disease has a 20-to-50-year latency period after asbestos exposure, and fewer than 5% of patients are diagnosed at stage I. [1][11] The cancer's rarity — approximately 3,000 new U.S. cases per year — limits the size of clinical studies needed to validate new diagnostic tools. Mesothelioma also lacks recurrent driver mutations, making standard genetic screening approaches less effective.

Should asbestos-exposed workers get regular biomarker screening?

No blood-based biomarker test is currently recommended for routine screening of asbestos-exposed individuals. Prospective studies have not demonstrated that SMRP screening improves outcomes in high-risk populations. However, asbestos-exposed workers should discuss their exposure history with their physician and undergo regular medical monitoring, including imaging when symptoms develop. Multi-marker panels and liquid biopsies in clinical trials represent the most promising path toward validated screening for high-risk groups.

References

Mesothelioma Treatment (PDQ) — Patient Version — National Cancer Institute
Malignant Mesothelioma Cancer Stat Facts — NCI SEER Program
Perioperative immunotherapy in resectable mesothelioma: a phase 2 trial and ctDNA analyses — Nature Medicine, 2025
A histomorphological atlas of resected mesothelioma discovered by AI — Nature Communications, 2025
Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies — Molecular Oncology, 2026 (IMPRESS assay)
Combined detection of SHOX2 and PTGER4 methylation with serum marker CYFRA21-1 for improved diagnosis of malignant pleural mesothelioma — Journal of Clinical Pathology, 2025
DNA methylation-based liquid biopsy for pleural mesothelioma (cfMeDIP-seq) — Journal of Clinical Oncology (ASCO 2025 Abstract)
Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma — Pass HI et al., New England Journal of Medicine, 2012
Napolitano A, Antoine DJ, Pellegrini L, et al. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients — Clinical Cancer Research, 2016;22(12):3087–3096.
FDA Grants Paige Breakthrough Device Designation for AI Cancer Detection — Paige, April 2025
Asbestos Exposure and Cancer Risk — National Cancer Institute
Baumann F, Flores E, Napolitano A, et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival — Carcinogenesis, 2015.
Cui A, Jin X, Zhai K, Tong Z, Shi H. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis — BMJ Open, 2014.
Ostroff RM, Mehan MR, Stewart A, Ayers D, Brody EN, Williams SA. Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool — PLoS ONE, 2012.
Clinical Study Deepens Understanding of Mesothelioma Treatment — Georgetown Lombardi Comprehensive Cancer Center, 2025
Nasu M, Emi M, Pastorino S, et al. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma — Journal of Thoracic Oncology, 2015.